From NIH
https://www.covid19treatmentguidelines.nih.gov/tables/table-2e/
Table 2e. Characteristics of Antiviral Agents That Are Approved or Under Evaluation for the Treatment of COVID-19
Last Updated: July 08, 2021
Dosing Regimens
The doses listed here are for approved indications or from reported experiences or clinical trials. Adverse Events Monitoring Parameters Drug-Drug Interaction Potential Comments and Links to Clinical Trials
Ivermectin
Adults:
The dose most commonly used in clinical trials is IVM 0.2–0.6 mg/kg PO given as a single dose or as a once-daily dose for up to 5 days.
Generally well tolerated
Dizziness
Pruritis
GI effects (e.g., nausea, diarrhea)
Neurological AEs have been reported when IVM has been used to treat parasitic diseases, but it is not clear whether these AEs were caused by IVM or the underlying conditions.
Monitor for potential AEs.
Minor CYP3A4 substrate
P-gp substrate
Generally given on an empty stomach with water; however, administering IVM with food increases its bioavailability.2
A list of clinical trials is available here: Ivermectin
Nitazoxanide
Adults:
Doses reported in COVID-19 studies range from NTZ 500 mg PO 3 times daily to 4 times daily.3,4 Higher doses are being studied (ClinicalTrials.gov Identifier NCT04746183).
Doses used for antiprotozoal indications range from NTZ 500 mg to 1 g PO twice daily.
Generally well tolerated
Abdominal pain
Diarrhea
Headache
Nausea
Vomiting
Urine discoloration
Ocular discoloration (rare)
Monitor for potential AEs.
Drug-drug interactions may occur if NTZ is administered concurrently with other highly plasma protein-bound drugs due to competition for binding sites.5
If NTZ is coadministered with other highly protein-bound drugs with narrow therapeutic indices, monitor the patient for AEs.
NTZ should be taken with food.
The oral suspension is not bioequivalent to the tablet formulation.
A list of clinical trials is available here: Nitazoxanide
a Infuse over 30–120 minutes.
b The FDA EUA permits the emergency use of RDV for the treatment of suspected COVID-19 or laboratory-confirmed SARS-CoV-2 infection in hospitalized pediatric patients weighing 3.5 kg to <40 kg or aged <12 years and weighing ≥3.5 kg.6SBECD = sulfobutylether-beta-cyclodextrin; ULN = upper limit of normal
sorry i cant help your reading comprehension, its under evaluation not approved ..good luck nih does research fda approves drugs
fda
Recommendation
There is insufficient evidence for the COVID-19 Treatment Guidelines Panel (the Panel) to recommend either for or against the use of ivermectin for the treatment of COVID-19. Results from adequately powered, well-designed, and well-conducted clinical trials are needed to provide more specific, evidence-based guidance on the role of ivermectin in the treatment of COVID-19.